Social StigmaNCT05925374
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care
A study testing Substance use stigma training in people with Social Stigma and Substance Use Disorders, run by Wayne State University at 1 site in United States.
Trial summary
This is a community-engaged research project that aims to identify and pilot test interventions that may reduce substance use stigma among professionals at primary care sites serving patients who might be exposed to HIV or are living with HIV. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Social Stigma, Substance Use Disorders, HIV Infections
- What is being tested?
- Substance use stigma training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2023to 7 Jun 2023
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Employed at a federally qualified health center (FQHC) or other primary care site
- For training and focus group participants (primary outcomes), volunteer is involved in direct interaction with patients
- For interview and trial feasibility survey participants (secondary outcomes), volunteer is a decision-maker at the FQHC and/or directly interacts with patients
Who cannot join
- Not formally employed at a primary care facility (e.g., volunteer position at the site)
Trial locations and contacts
1 site in 1 country.
About this study
This is a community-engaged research project that aims to identify and pilot test interventions that may reduce substance use stigma among professionals at primary care sites serving patients who might be exposed to HIV or are living with HIV. Our goal is to develop a multi-level substance use stigma intervention that leverages 1) education and 2) organizational policy to address structural drivers of stigma and the stigmatizing professional attitudes and behaviors that affect patients. Hypothesis: the results of the trial pilot research and are expected to provide scientific evidence demonstrating feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training. We plan to build on the data from this pilot trial study to then further test the multi-level intervention in another larger trial study with primary care organizations to determine whether the intervention addresses multiple complex drivers of substance use stigma that influence HIV prevention and care outcomes among people who use drugs.
Read the detailed description
This planning project aims to develop and pilot test elements of a multi-level substance use stigma reduction intervention. This study builds on past research indicating educational interventions can meaningfully reduce provider stigma related to substance use by examining the extent to which educational interventions may be enhanced by organizational policies addressing structural drivers of stigma toward people who use drugs operating in the health sector. The ultimate goal of this pilot study is to identify feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training and that could be tested in a larger subsequent trial study.
This project will use a community-engaged approach with federally-qualified health centers (FQHCs) and other primary care sites to generate pilot data and establish protocols that not only measure self-reported changes in attitudes among health professionals but also use patient surveys and electronic medical records to measure the effect of educational and policy interventions on changes to clinical practice and patient outcomes.
Initial planning will focus on developing and pilot testing an educational curriculum (Aim 1) that addresses key drivers of provider-based stigma and FQHC facility recruitment and participation in policy development to address structural stigma (Aim 2). The latter half of the planning process will focus on refining and finalizing the trial design, survey instruments, data collection and management procedures, and drafting the trial protocol (Aim 3).
For Aim 1, the project team will design a curriculum addressing stigma related to substance use among the primary care workforce. The study team will prepare a 2-hour interactive curriculum to be used in an education session for individuals in any professional role (providers, other clinical support staff, and receptionists). The lead PI, Dr. Madden, will co-teach the course with a community consultant who has firsthand experience with SUD and harm reduction work. Including a co-teacher with such firsthand experience provides a contact-based approach to reducing stigma, which has been shown to reduce stigmatizing professional attitudes in several past studies. The curriculum will be piloted with ~35 primary care professionals, including physicians, other clinical support staff, and reception staff to assess changes to attitudes and intended behaviors that are indicative of substance use stigma. These changes will be assessed using validated surveys of provider-based stigma and new survey measures using the Theory of Planned Behavior to assess factors influencing professional behavior. A focus group with 6-10 pilot participants will be used to obtain qualitative feedback on the curriculum in order to refine and revise the training for the subsequent trial. The focus group will follow a Qualitative Description Approach, a methodology used in health services research to explore perspectives and experiences among people directly involved in a health/social phenomenon.
For Aim 2, FQHCs and other primary care sites providing HIV prevention and care services will be identified and approached in year 1 by the PIs. PIs will meet with interested FQHC administrators to explain the trial planning project and those administrators who agree to participate in trial planning will be asked to allow administrators and personnel to volunteer for qualitative interviews regarding facility policies and practices affecting stigma and HIV prevention and care for people who use drugs. In-depth semi-structured interviews with 15-20 FQHC professionals will be conducted in order to identify a suitable stigma policy to test in a larger subsequent trial study. Interviews will also be guided by the Qualitative Description Approach. Analyses will occur simultaneously with data collection and use thematic analysis. A policy proposal based on the qualitative analysis will be provided to FQHCs, and revised based on their feedback.
For Aim 3, the study team will collaborate with designated representatives ("champions") from each primary care site to design and finalize a trial protocol that tests a multi-level stigma intervention combining professional education and policy changes aimed at stigma reduction. The study team will work with the site champions in quarterly or monthly meetings (depending on scheduling availability of the champions) to review results from the training surveys, focus groups, and policy interviews, and to assure protocol feasibility and that site feedback is integrated into the pilot study and the ultimate goal of planning a larger subsequent trial study plans. A draft of the trial protocol will be provided to FQHC personnel along with anonymous online surveys soliciting feedback. The feedback will be analyzed by the project team and the organizational project champions, and the protocol will be revised.
The initial plan for the larger trial study that this pilot trial will inform includes a cluster randomized trial with 8 primary care sites and 80 primary care providers. Primary care providers will be the primary sampling units (i.e., the clusters), and patients will be the secondary sampling units. Randomization will first happen at the FQHC level so that all providers at a facility receive the same intervention in one of four arms: 1) facilities where personnel receive an educational intervention addressing provider-based stigma and facilities implement policy change aimed at reducing structural stigma toward PWUD; 2) facilities where personnel receive an educational intervention, but do not alter policies; 3) facilities that implement policy change, but personnel do not receive an educational intervention; and 4) control facilities without intervention implementation. For 20 random providers, 20 patients with substance use disorders (~400 patients total) will be selected in a second stage of randomization for survey participation. Patient surveys will include validated measures of anticipated, received, and internalized stigma, as well as validated tools to assess treatment adherence and use of harm reduction and substance use treatment services. Aggregated de-identified electronic medical records data from all patients of all participating providers will also be assessed as secondary sampling units. These patient outcomes for each primary care provider will be assessed to determine the effect of the multi-level stigma intervention. Electronic medical records and survey data will be collected for all arms at baseline and every 6 months for 24 months. Other clinical staff (e.g., nurses) and reception staff who interact with patients will be included in educational interventions, and may too be affected by policy changes (to be determined by outcomes of Aim 2), but will not be a primary sampling unit. The trial will require a separate IRB approval, and the current IRB approval is only for the pilot trial and planning activities in the R34.
- Being tested
- Substance use stigma training
- Keywords
- community-engaged research, Provider-based stigma, Structural stigma
- Medical subject headings
- Social Stigma, Substance-Related Disorders, HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Substance use stigma trainingBehavioural
The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
| Study group | Role | What they receive |
|---|---|---|
| Training group | Experimental | Professionals working at a primary care site who has direct interaction with patients. They receive a one-time 2-hour interactive in-person training focused on improving care for patients who use drugs and reducing provider-based stigma. Their baseline attitudes and intended actions are compared to their post-intervention answers to questions in the same domains. Thus, the participants act as their own comparison group, where baseline answers are compared to post-intervention answers. Receives: Behavioral: Substance use stigma training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Provider-based Stigma (Social Distance Scale (SDS) Measure)
This measure assesses how much "social distance" (level of contact/closeness they would prefer in social situations) that a respondent wants to have from a group of people. Four items from the social distance scale (SDS) adapted to people who use drugs. As reported in surveys taken by primary care professionals. Higher score= less social distance and less stigma. Minimum score on each SDS scale= 4; maximum score= 20. The intervention sought to promote higher scores (less desire for social distance, less stigma).
Measured: Change from baseline SDS score (measured 0-28 days prior to training) at 0-7 days post-training (pre/post design)
Provider-based Stigma (Medical Condition Regard Scale (MCRS) Measure)
This measure assesses how positively healthcare professionals perceive a group of patients. Items from the Medical condition regard scale (MCRS) were adapted to patients who use drugs. As reported in surveys taken by primary care professionals. Higher score= more acceptance of the patient and lower stigma. Minimum score=7; maximum score=35. The intervention sought to promote higher scores (more acceptance, less stigma).
Measured: Change from baseline MCRS score (measured 0-28 days prior to training) at 0-7 days post-training (pre/post design)
Provider-based Stigma (Planned Behavior Measure Assessing Intention to Help Patients Who Use Drugs)
This measure used a single questions asking their level of agreement with the statement, "I intend to engage with patients who use drugs and help them to get evidence-based services over the next 3 months." This was reported in surveys taken by primary care professionals to assess planned stigmatizing actions based on the Theory of Planned Behavior. Higher score= more intention to help people who use drugs and less stigma. Maximum value=5; minimum value=1. The intervention sought to promote higher scores (more intention to help).
Measured: Change from baseline planned behavior score (measured 0-7 days prior to training) at 0-7 days post-training (pre/post design)
Number of Participants Who Completed Focus Groups on Training Feasibility
The feasibility of the training was qualitatively assessed in focus groups using verbal feedback from participants. There was no quantification of this outcome other than counting how many participants provided feedback in the focus groups, and instead the feasibility of the training was assessed using thematic analysis, in which verbatim transcripts are read through and assigned brief analytic "codes" that briefly qualitatively summarize the content of participant feedback.
Measured: up to 5 months after the training
Secondary outcomes (1)
Number of Participants Who Completed Qualitative Interviews on Policy Feasibility
Qualitatively assessed in in-depth interviews with primary care personnel. There was no quantification of this outcome other than counting how many participants provided feedback in the interviews, and instead the feasibility of the training was assessed using thematic analysis, in which verbatim transcripts are read through and assigned brief analytic "codes" that briefly qualitatively summarize the content of participant feedback.
Measured: One-time interview lasting 45-60 minutes per participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2023
- Study start1 Feb 2023
- Primary completion17 May 2023
- Study completion7 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Social StigmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study will pilot test a substance use training that aims to reduce professional stigma towards patients who use drugs. Participants will be professionals working in primary care settings, and all participants will receive the intervention (training). Their stigmatizing attitudes and intended/planned behaviors will be assessed immediately prior to the training and immediately after the training.
- Masking
- None (open label)
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wayne State University
- Sponsor type
- University, hospital or other
- Collaborators
- Loyola University Chicago, National Institute on Drug Abuse (NIDA)
- Responsible party
- Principal investigator, Erin F. Madden, Wayne State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05925374
- Sponsor's protocol ID
- R34DA053758
- Other IDs
- 5R34DA053758-03
- Status last verified
- Dec 2025
- First submitted
- 12 Jun 2023
- Last updated
- 14 Jan 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to make the pilot training survey data or the qualitative interview data about the stigma policies.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care
- ClinicalTrials.gov ID
- NCT05925374
- Acronym / sponsor ID
- R34DA053758
- Keywords
- community-engaged research, Provider-based stigma, Structural stigma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Wayne State UniversityUniversity, hospital or other
- Collaborators
- Loyola University Chicago, National Institute on Drug Abuse (NIDA)
- Study start
- 1 Feb 2023 (actual)
- Primary completion
- 17 May 2023 (actual)
- Study completion
- 7 Jun 2023 (actual)
- First posted
- 29 Jun 2023 (actual)
- Results
- Posted 14 Jan 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a community-engaged research project that aims to identify and pilot test interventions that may reduce substance use stigma among professionals at primary care sites serving patients who might be exposed to HIV or are living with HIV. Our goal is to develop a multi-level substance use stigma intervention that leverages 1) education and 2) organizational policy to address structural drivers of stigma and the stigmatizing professional attitudes and behaviors that affect patients. Hypothesis: the results of the trial pilot research and are expected to provide scientific evidence demonstrating feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training. We plan to build on the data from this pilot trial study to then further test the multi-level intervention in another larger trial study with primary care organizations to determine whether the intervention addresses multiple complex drivers of substance use stigma that influence HIV prevention and care outcomes among people who use drugs.
Detailed description
This planning project aims to develop and pilot test elements of a multi-level substance use stigma reduction intervention. This study builds on past research indicating educational interventions can meaningfully reduce provider stigma related to substance use by examining the extent to which educational interventions may be enhanced by organizational policies addressing structural drivers of stigma toward people who use drugs operating in the health sector. The ultimate goal of this pilot study is to identify feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training and that could be tested in a larger subsequent trial study.
This project will use a community-engaged approach with federally-qualified health centers (FQHCs) and other primary care sites to generate pilot data and establish protocols that not only measure self-reported changes in attitudes among health professionals but also use patient surveys and electronic medical records to measure the effect of educational and policy interventions on changes to clinical practice and patient outcomes.
Initial planning will focus on developing and pilot testing an educational curriculum (Aim 1) that addresses key drivers of provider-based stigma and FQHC facility recruitment and participation in policy development to address structural stigma (Aim 2). The latter half of the planning process will focus on refining and finalizing the trial design, survey instruments, data collection and management procedures, and drafting the trial protocol (Aim 3).
For Aim 1, the project team will design a curriculum addressing stigma related to substance use among the primary care workforce. The study team will prepare a 2-hour interactive curriculum to be used in an education session for individuals in any professional role (providers, other clinical support staff, and receptionists). The lead PI, Dr. Madden, will co-teach the course with a community consultant who has firsthand experience with SUD and harm reduction work. Including a co-teacher with such firsthand experience provides a contact-based approach to reducing stigma, which has been shown to reduce stigmatizing professional attitudes in several past studies. The curriculum will be piloted with ~35 primary care professionals, including physicians, other clinical support staff, and reception staff to assess changes to attitudes and intended behaviors that are indicative of substance use stigma. These changes will be assessed using validated surveys of provider-based stigma and new survey measures using the Theory of Planned Behavior to assess factors influencing professional behavior. A focus group with 6-10 pilot participants will be used to obtain qualitative feedback on the curriculum in order to refine and revise the training for the subsequent trial. The focus group will follow a Qualitative Description Approach, a methodology used in health services research to explore perspectives and experiences among people directly involved in a health/social phenomenon.
For Aim 2, FQHCs and other primary care sites providing HIV prevention and care services will be identified and approached in year 1 by the PIs. PIs will meet with interested FQHC administrators to explain the trial planning project and those administrators who agree to participate in trial planning will be asked to allow administrators and personnel to volunteer for qualitative interviews regarding facility policies and practices affecting stigma and HIV prevention and care for people who use drugs. In-depth semi-structured interviews with 15-20 FQHC professionals will be conducted in order to identify a suitable stigma policy to test in a larger subsequent trial study. Interviews will also be guided by the Qualitative Description Approach. Analyses will occur simultaneously with data collection and use thematic analysis. A policy proposal based on the qualitative analysis will be provided to FQHCs, and revised based on their feedback.
For Aim 3, the study team will collaborate with designated representatives ("champions") from each primary care site to design and finalize a trial protocol that tests a multi-level stigma intervention combining professional education and policy changes aimed at stigma reduction. The study team will work with the site champions in quarterly or monthly meetings (depending on scheduling availability of the champions) to review results from the training surveys, focus groups, and policy interviews, and to assure protocol feasibility and that site feedback is integrated into the pilot study and the ultimate goal of planning a larger subsequent trial study plans. A draft of the trial protocol will be provided to FQHC personnel along with anonymous online surveys soliciting feedback. The feedback will be analyzed by the project team and the organizational project champions, and the protocol will be revised.
The initial plan for the larger trial study that this pilot trial will inform includes a cluster randomized trial with 8 primary care sites and 80 primary care providers. Primary care providers will be the primary sampling units (i.e., the clusters), and patients will be the secondary sampling units. Randomization will first happen at the FQHC level so that all providers at a facility receive the same intervention in one of four arms: 1) facilities where personnel receive an educational intervention addressing provider-based stigma and facilities implement policy change aimed at reducing structural stigma toward PWUD; 2) facilities where personnel receive an educational intervention, but do not alter policies; 3) facilities that implement policy change, but personnel do not receive an educational intervention; and 4) control facilities without intervention implementation. For 20 random providers, 20 patients with substance use disorders (~400 patients total) will be selected in a second stage of randomization for survey participation. Patient surveys will include validated measures of anticipated, received, and internalized stigma, as well as validated tools to assess treatment adherence and use of harm reduction and substance use treatment services. Aggregated de-identified electronic medical records data from all patients of all participating providers will also be assessed as secondary sampling units. These patient outcomes for each primary care provider will be assessed to determine the effect of the multi-level stigma intervention. Electronic medical records and survey data will be collected for all arms at baseline and every 6 months for 24 months. Other clinical staff (e.g., nurses) and reception staff who interact with patients will be included in educational interventions, and may too be affected by policy changes (to be determined by outcomes of Aim 2), but will not be a primary sampling unit. The trial will require a separate IRB approval, and the current IRB approval is only for the pilot trial and planning activities in the R34.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This study will pilot test a substance use training that aims to reduce professional stigma towards patients who use drugs. Participants will be professionals working in primary care settings, and all participants will receive the intervention (training). Their stigmatizing attitudes and intended/planned behaviors will be assessed immediately prior to the training and immediately after the training.
| Arm | Type | Receives |
|---|---|---|
| Training group | Experimental | Behavioral: Substance use stigma trainingProfessionals working at a primary care site who has direct interaction with patients. They receive a one-time 2-hour interactive in-person training focused on improving care for patients who use drugs and reducing provider-based stigma. Their baseline attitudes and intended actions are compared to their post-intervention answers to questions in the same domains. Thus, the participants act as their own comparison group, where baseline answers are compared to post-intervention answers. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Employed at a federally qualified health center (FQHC) or other primary care site
- For training and focus group participants (primary outcomes), volunteer is involved in direct interaction with patients
- For interview and trial feasibility survey participants (secondary outcomes), volunteer is a decision-maker at the FQHC and/or directly interacts with patients
Key exclusion criteria (1 listed)
- Not formally employed at a primary care facility (e.g., volunteer position at the site)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Substance use stigma trainingThe intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs. | Behavioural | Training group |
Primary outcome
Provider-based Stigma (Social Distance Scale (SDS) Measure)
Time frame: Change from baseline SDS score (measured 0-28 days prior to training) at 0-7 days post-training (pre/post design)
This measure assesses how much "social distance" (level of contact/closeness they would prefer in social situations) that a respondent wants to have from a group of people. Four items from the social distance scale (SDS) adapted to people who use drugs. As reported in surveys taken by primary care professionals. Higher score= less social distance and less stigma. Minimum score on each SDS scale= 4; maximum score= 20. The intervention sought to promote higher scores (less desire for social distance, less stigma).
Provider-based Stigma (Medical Condition Regard Scale (MCRS) Measure)
Time frame: Change from baseline MCRS score (measured 0-28 days prior to training) at 0-7 days post-training (pre/post design)
This measure assesses how positively healthcare professionals perceive a group of patients. Items from the Medical condition regard scale (MCRS) were adapted to patients who use drugs. As reported in surveys taken by primary care professionals. Higher score= more acceptance of the patient and lower stigma. Minimum score=7; maximum score=35. The intervention sought to promote higher scores (more acceptance, less stigma).
Provider-based Stigma (Planned Behavior Measure Assessing Intention to Help Patients Who Use Drugs)
Time frame: Change from baseline planned behavior score (measured 0-7 days prior to training) at 0-7 days post-training (pre/post design)
This measure used a single questions asking their level of agreement with the statement, "I intend to engage with patients who use drugs and help them to get evidence-based services over the next 3 months." This was reported in surveys taken by primary care professionals to assess planned stigmatizing actions based on the Theory of Planned Behavior. Higher score= more intention to help people who use drugs and less stigma. Maximum value=5; minimum value=1. The intervention sought to promote higher scores (more intention to help).
Number of Participants Who Completed Focus Groups on Training Feasibility
Time frame: up to 5 months after the training
The feasibility of the training was qualitatively assessed in focus groups using verbal feedback from participants. There was no quantification of this outcome other than counting how many participants provided feedback in the focus groups, and instead the feasibility of the training was assessed using thematic analysis, in which verbatim transcripts are read through and assigned brief analytic "codes" that briefly qualitatively summarize the content of participant feedback.
1 secondary outcome
Number of Participants Who Completed Qualitative Interviews on Policy Feasibility
Time frame: One-time interview lasting 45-60 minutes per participant
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No. There is no plan to make the pilot training survey data or the qualitative interview data about the stigma policies.
Related trials for Social Stigma
Not yet recruiting
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
Schizophrenia, Schizoaffective Disorder
Recruiting
AI Simulation to Reduce Stigma and Enhance Psychiatric Readiness in Nursing Students
Mental Illness Stigma, Psychiatric Nursing
Not yet recruiting
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
Suicide, Mental Health Stigma
Active, not recruiting
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Cervical Cancer Screening
Not yet recruiting
Testing a Multi-Level Approach to Reduce Stigma for Women Living With HIV
HIV (Human Immunodeficiency Virus)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Substance use stigma training in people with Social Stigma and Substance Use Disorders, run by Wayne State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Provider-based Stigma (Social Distance Scale (SDS) Measure) (time frame: Change from baseline SDS score (measured 0-28 days prior to training) at 0-7 days post-training (pre/post design)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.